Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025 along with the Limited Review Report for the said period.
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Solara Active Pharma Sciences reported weak Q2 FY26 results, swinging to a consolidated loss of Rs. 10.10 crore from a profit of Rs. 8.01 crore in Q2 FY25. Revenue from operations fell to Rs. 313.54 crore (down ~9.6% YoY from Rs. 346.95 crore). For H1 FY26, revenue declined ~10.9% YoY to Rs. 632.69 crore, though the company posted a marginal profit of Rs. 0.42 crore versus a loss of Rs. 5.45 crore last year. EPS for the quarter stood at Rs. (2.36). The auditor (Deloitte Haskins & Sells LLP) issued an unmodified review conclusion on both standalone and consolidated results.
Negative near-term sentiment is likely as the sharp swing to a quarterly loss and ongoing revenue decline raise concerns. Importantly, the company disclosed accumulated losses of Rs. 314.25 crore and net current liabilities exceeding net current assets by Rs. 72.69 crore, requiring a going concern basis justification, with the pending Rs. 134.99 crore final rights issue call being crucial for funding operations.